2006/038 NICE issues final guidance on trastuzumab
NICE has today (Wednesday 23 August 2006) issued final guidance on Herceptin to the NHS, just three months after the drug was licensed by the regulatory authorities for use in early breast cancer. NICE recommends Herceptin for women with early stage HER2-positive breast cancer, except where there are concerns about the woman's cardiac function.
 |
2006/038 NICE issues final guidance on trastuzumab 23 August 2006 (43.1Kb 15sec @ 28.8Kbps) |
